← Therapy pipeline
Investigational · Obesity development

Bimagrumab

Eli Lilly

Activin type II receptor antibody investigated with incretin therapy.

activin II receptor
Other study areas
Body composition
Selected program areas, not approvals. See the full profile for individual trials.
Obesity stagePhase 2Updated as of November 2026
SponsorEli Lilly
Targetsactivin II receptor
RouteInfusion
DevelopmentObesity-specific
01 / Evidence

Selected study results

Bimagrumab + semaglutide vs semaglutideWeight changeBody weight decreased 17.8 kg · 48 weeks · Phase 2
Phase 2 · Infusion · Peer-reviewed results

Weight change · 48 weeks

Study focus: Weight management without type 2 diabetes

Investigational regimen
17.8 kg
Placebo / comparator
14.2 kg

Adults with obesity without diabetes · Bimagrumab 30 mg/kg IV + semaglutide 2.4 mg vs semaglutide 2.4 mg · Trial N=507 · Least-squares mean kilograms; selected trial arms, not a cross-trial comparison. Results & methods ↗

Bimagrumab monotherapy · body composition with type 2 diabetesMean total body-fat mass changeFat mass decreased 20.5% · 48 weeks · Phase 2
Phase 2 · Infusion · Peer-reviewed results

Mean total body-fat mass change · 48 weeks

Study focus: Body composition with type 2 diabetes

Bimagrumab
20.5%
Placebo
0.5%

Adults with type 2 diabetes and BMI 28–40 kg/m² · 10 mg/kg IV, maximum 1,200 mg, every four weeks · Trial N=75 · Least-squares means; analysis restricted to participants completing treatment. Results & methods ↗ · Publication ↗

Additional results or analyses from this same study
  • Other endpoints · same studyBody weight changed by −6.5% versus −0.8%; lean mass by +3.6% versus −0.8%; HbA1c by −0.76 versus +0.04 percentage points.

Fat-mass change is not body-weight change. Only 58 of 75 participants completed 48 weeks; the completer analysis limits interpretation.

Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.

02 / How it works

Mechanism at a glance

GLP-1GLP-1—
GIPGIP—
GCGglucagon—
AMYamylin—
OTHOther targetsTargeted

Body-composition and other targets appear alongside hormone pathways in this overview.

Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

IV antibodyInfusion · Every 12 weeks in studied regimen
Phase 2Trial published
Milestone → next

Latest: Phase 2 semaglutide combination trial published.

Next: Results from the completed Phase 2 bimagrumab/tirzepatide study NCT06643728; the registry lists no posted results.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 2 studies2 records

Phase 2

Bimagrumab + tirzepatide · completed Phase 2

Weight management / body composition
Study: CompletedResults: No registry results postedStatus reviewed November 2026

Separate Phase 2 combination study completed October 27, 2026; 252 actual participants and a week-24 body-weight primary endpoint. No registry results are posted. This is distinct from withdrawn, zero-enrollment NCT06901349.

Phase 2

Bimagrumab with or without semaglutide

Body composition and weight management
Study: CompletedResults: Published results linked aboveStatus reviewed November 2026

507-adult randomized obesity study; bimagrumab monotherapy, semaglutide, and combination groups are arms within the same trial.

Related conditions and outcomes

Phase 2 studies2 records

Phase 2

Bimagrumab + tirzepatide

Combination development
Study: WithdrawnResults: No registry results posted yetStatus reviewed November 2026

Separate combination protocol withdrawn before enrollment (zero participants), for strategic business reasons; distinct from completed NCT06643728.

Phase 2

Bimagrumab monotherapy in type 2 diabetes and obesity

Body composition with type 2 diabetes
Study: CompletedResults: Peer-reviewed results shown aboveStatus reviewed November 2026

Published 48-week study of fat mass, lean mass, weight and glycemic outcomes; distinct from the later combination trial.